Search Results
Aug 04, 2026, 16:05 ET Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Phase 2a/b, multicenter, open-label study designed with pivotal intent to evaluate the efficacy and safety of oral dabogratinib at two QD doses (60 mg and 80 mg) in participants with low-grade upper tract urothelial carcinoma (LG-UTUC), a rare cancer where approximately 85% of tumors are driven by FGFR3.
More news about: Tyra Biosciences
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
completed enrollment of patients with relapsing-remitting multiple sclerosis.A randomized, double-blind, comparative clinical study of ABP 938 (8 mg) compared with EYLEA HD® (aflibercept) was initiated and is enrolling patients with neovascular age-related macular degeneration.TEZSPIRE
More news about: Amgen
Aug 04, 2026, 09:00 ET Playa Bowls Brings Superfruit Functional Benefits to Refreshers with Surf Quenchers
caffeine-free or customized with optional plant-powered energy. The energy boost, naturally sourced from green coffee bean extract, provides approximately 70 mg of caffeine. Individually hand-crafted in a shaker, poured over ice and made fresh to order, each drink puts the preparation on display before the first
More news about: Playa Bowls
Aug 04, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete Activation System with 5-11× More Usable B1 Plus the Cofactors That Unlock It
formula that actually works."BioActive Vitamin B1™ features 150mg benfotiamine (≥98% purity), 15mg pyridoxal-5'-phosphate (≥98.5% purity), 100mg magnesium bisglycinate chelate (providing 18mg elemental magnesium), and 100mg alpha-lipoic acid (≥99% purity) in a size 0 HPMC vegetarian capsule. The
More news about: Triquetra Health LLC
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
Aug 04, 2026, 01:25 ET Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa
be validated. In the China‑based ENLIGHT phase Ⅱb study, subjects receiving 20 mg once weekly (Q1W) for 18 weeks achieved a mean weight reduction of 10.6% and a waist circumference decrease of approximately 8.9 cm; the 20 mg once‑every‑two‑weeks (Q2W) group showed a mean weight loss of 9.7%, with improvements
More news about: Innogen Pharmaceuticals
Aug 03, 2026, 17:29 ET Physician's Choice 60 Billion Probiotic® Advanced to Launch in 625 Costco Warehouses Nationwide
include B. lactis Bl-04® (HOWARU®) and B. lactis HN019™ (HOWARU®), two strains that have been examined in clinical research.It also includes 20 mg of heat-treated L. gasseri CP2305, a postbiotic that has been studied in clinical settings. Physician's Choice says the ingredient was included as part
More news about: Physician’s Choice
Aug 03, 2026, 11:00 ET Seegene propone un enfoque integral para la detección de infecciones del tracto reproductivo mediante el Global Million Clinical Study (GMCS)
objetivo de la prueba de ITS Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), virus del herpes
More news about: Seegene Inc.
Aug 03, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete B1 Activation System with 600mg Research-Matched Dose and Full Cofactor Support
(S-benzoylthiamine-O-monophosphate), 30mg Pyridoxal-5'-Phosphate (active B6, USP grade ≥98.5% purity), 200mg Magnesium Bis-glycinate (providing 36mg elemental magnesium), and 300mg Alpha-Lipoic Acid (≥99% purity). The formulation is delivered in vegetarian HPMC capsules, manufactured in FDA-registered, cGMP-certified
More news about: Triquetra Health LLC
Aug 03, 2026, 07:30 ET Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
patients taking low-dose aspirin, eg, up to 150 mg per day) were excluded from participating in these studies. Therefore, the efficacy and safety of XIAFLEX in patients receiving anticoagulant medications (other than low-dose aspirin, eg, up to 150 mg per day) within 7 days prior to XIAFLEX administration
More news about: Keenova Therapeutics
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
2 mg/kg ASC30,1 mg/kg ASC48，和0.1 mg/kg ASC39口服，每日一次
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
Europe, and Canada. The two pivotal studies will investigate the long-term efficacy, safety, and tolerability of three maintenance doses (20 mg, 40 mg and 60 mg) of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without type 2 diabetes (AURORA-1) and in participants
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 03:00 ET Seegene promuove un approccio completo alla diagnosi delle infezioni dell'apparato riproduttivo attraverso il Global Million Clinical Study (GMCS)
(STI).Analiti target dei test per le STIChlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Trichomonas vaginalis (TV), Mycoplasma hominis (MH), Ureaplasma urealyticum (UU), Ureaplasma parvum (UP), virus herpes
More news about: Seegene Inc.
Aug 03, 2026, 02:22 ET MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
than 50% in premarket trading after its Phase 2 trial reported mixed results for its schizophrenia drug candidate. According to the Company, "The 330/6 mg once-daily dose, which results in lower daily exposure than BID dosing, demonstrated numerical improvement over placebo, but did not achieve statistical
More news about: Schall, Brown & Schwartz LLP
Jul 31, 2026, 14:48 ET American Regent, Inc. Animal Health Issues Nationwide Recall of two lots of Adequan® Canine and two lots of Adequan® i.m. due to visible glass fiber material in the product
nationwide recall of two lots (25011 and 3369) of Adequan® Canine Injection (for dogs), 100 mg/mL 5 mL multi-dose vials and two lots (24416 and 25265P) of Adequan® i.m. Injection (for horses), 500 mg/5 mL single-dose 5 mL vials to the consumer level. The products are being recalled due to the
More news about: American Regent, Inc.
Jul 31, 2026, 12:20 ET KLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ
jiných než lipoproteinů s vysokou hustotou (non-HDL-C) ≥ 120 mg/dL nebo hladinu apolipoproteinu B ≥ 80 mg/dL; a byli léčeni nejvyšší tolerovanou dávkou statinu a/nebo ezetimibu. Medián výchozí hodnoty LDL-C činil 122 mg/dL (IQR, 104–149 mg/dL) podle výsledků místních laboratorních testů. Účastníci byli
More news about: Amgen
Jul 30, 2026, 16:06 ET Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:05 ET Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
the next year, including the submission of our sNDA, the potential addition of selinexor to relevant compendia guidelines and topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial, each anticipated in the second half of 2026."About the Phase 3 XPORT-EC-042 TrialEC-042 (XPORT-EC-042;
More news about: Karyopharm Therapeutics Inc.
Jul 30, 2026, 16:01 ET PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
PIVOT-HD 24-month results demonstrated dose-dependent disease slowing on cUHDRS scale in Stage 2 participants, reaching 52% at 10 mg dose levelPlan to engage with FDA in 2H 2026 to discuss PIVOT-HD 24-month results being finalizedINVEST-HD study being conducted and
More news about: PTC Therapeutics, Inc.
Jul 30, 2026, 13:07 ET POSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL
≥ 90 mg/dl, oder ein Nicht-HDL-Cholesterin (Non-HDL-C) von ≥ 120 mg/dL oder ein Apolipoprotein B von ≥ 80 mg/dL aufwiesen und mit der höchstverträglichen Dosis eines Statins und/oder Ezetimib behandelt wurden. Der Medianwert des LDL-C-Ausgangswerts lag bei lokalen Laboruntersuchungen bei 122 mg/dl (IQR:
More news about: Amgen
Jul 30, 2026, 12:45 ET AVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC
cholestérol (non HDL-C) ≥ 120 mg/dL ou un taux d'apolipoprotéine B ≥ 80 mg/dL et qui ont reçu la dose maximale tolérée de statine et/ou d'ézétimibe. Le taux médian de LDL-C à l'inclusion était de 122 mg/dL (écart interquantile : 104-149 mg/dL), d'après les analyses effectuées par un laboratoire local.
More news about: Amgen
Jul 30, 2026, 12:40 ET Lupin Announces U.S. FDA Approval and Launch of Sugammadex Injection
Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States.
More news about: Lupin Pharmaceuticals, Inc.
Jul 30, 2026, 09:25 ET POZITÍVNE STANOVISKO VÝBORU PRE LIEKY NA HUMÁNNE POUŽITIE PODPORUJE ŠIRŠIE POUŽÍVANIE LIEKU REPATHA® OD SPOLOČNOSTI AMGEN PRED PRVÝM INFARKTOM ALEBO MOZGOVOU PRÍHODOU
cholesterol lipoproteínov bez vysokej hustoty (non-HDL-C) ≥ 120 mg/dl alebo apolipoproteín B ≥ 80 mg/dl, a boli liečení najvyššou tolerovanou dávkou statínu a/alebo ezetimibu. Medián východiskovej hodnoty LDL-C bol 122 mg/dl (IQR, 104 – 149 mg/dl) podľa lokálnych laboratórnych testov. Účastníci boli randomizovaní
More news about: Amgen
Jul 30, 2026, 08:30 ET LA OPINIÓN FAVORABLE DEL CHMP RESPALDA UN USO MÁS AMPLIO DE REPATHA® DE AMGEN
colesterol no lipoproteína de alta densidad (n- HDL-C) ≥ 120 mg/dL o apolipoproteína B ≥ 80 mg/dL, y tratados con la dosis máxima tolerada de estatina y/o ezetimiba. La mediana del nivel basal de LDL-C fue de 122 mg/dL (IQR: 104-149 mg/dL) según las pruebas de laboratorio locales. Los participantes fueron
More news about: Amgen
Jul 30, 2026, 08:30 ET MAINGEAR Unveils Next-Gen 'Zero' Gaming Desktop PCs: Engineered for Unrelenting Performance, Designed for Unobstructed Visibility
intentional against the wraparound glass.Zero Cables. Zero Obstructions.MAINGEAR's patented MG-RC (MAINGEAR Rear Connection) technology is a defining feature of the Zero lineup. MG-RC routes all motherboard connectors to the rear and underside of the board, eliminating visible motherboard
More news about: MAINGEAR